drugset / Trial / NCT06291064
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2029-06
- Completion
- 2032-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Epirubicin | Small molecule | — | Intravenous |